Model the potential national health benefits and medical savings from reduced daily intake of calories, sodium, and saturated fat among the U.S. adult population.
Design.
Simulation based on secondary data analysis; quantitative research. Measures include the prevalence of overweight/obesity, uncontrolled hypertension, elevated cholesterol, and related chronic conditions under various hypothetical dietary changes.
Setting.
United States.
Subjects.
Two hundred twenty-four million adults.
Measures.
Findings come from a Nutrition Impact Model that combines information from national surveys, peer-reviewed studies, and government reports.
Analysis.
The simulation model predicts disease prevalence and medical expenditures under hypothetical dietary change scenarios.
Results.
We estimate that permanent 100-kcal reductions in daily intake would eliminate approximately 71.2 million cases of overweight/obesity and save $58 billion annually. Long-term sodium intake reductions of 400 mg/d in those with uncontrolled hypertension would eliminate about 1.5 million cases, saving $2.3 billion annually. Decreasing 5 g/d of saturated fat intake in those with elevated cholesterol would eliminate 3.9 million cases, saving $2.0 billion annually.
Conclusions.
Modest to aggressive changes in diet can improve health and reduce annual national medical expenditures by $60 billion to $120 billion. One use of the model is to estimate the impact of dietary change related to setting public health priorities for dietary guidance. The findings here argue that emphasis on reduction in caloric intake should be the highest priority.
AllisonDBZannolliRNarayanKM. The direct health care costs of obesity in the United States. Am J Public Health.1999;89:1194–1199.
2.
AndersonLHMartinsonBCCrainAL. Health care charges associated with physical inactivity, overweight, and obesity. Prev Chronic Dis.2005;2:A09.
3.
ColditzGA. Economic costs of obesity and inactivity. Med Sci Sports Exerc.1999;31(11 suppl):S663–S667.
4.
FinkelsteinEAFiebelkornICWangG. National medical spending attributable to overweight and obesity: how much, and who's paying?Health Aff (Millwood). 2003;Suppl Web Exclusives:W3–W26. Available at: http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.219vl. Accessed May 26, 2008.
5.
FinkelsteinEARuhmCJKosaKM. Economic causes and consequences of obesity. Annu Rev Public Health.2005;26:239–257.
6.
MokdadAHFordESBowmanBA. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA.2003;289:76–79.
7.
QuesenberryCPCaanBJacobsonA. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med.1998;158:466–472.
8.
RosamondWFlegalKFridayG. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation.2007;115:e69–e171.
9.
RosamondWFlegalKFurieK. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation.2008;117:e25–e146.
10.
SchmierJKJonesMLHalpernMT. Cost of obesity in the workplace. Scand J Work Environ Health.2006;32:5–11.
WeeCCPhillipsRSLegedzaAT. Health care expenditures associated with overweight and obesity among US adults: importance of age and race. Am J Public Health.2005;95:159–165.
13.
WolfAMColditzGA. Current estimates of the economic cost of obesity in the United States. Obes Res.1998;6:97–106.
14.
WyattSBWintersKPDubbertPM. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci.2006;331:166–174.
15.
ZarragaIGESchwarzERM. Impact of dietary patterns and interventions on cardiovascular health. [review]. Circulation.2006;114:961–973.
16.
ChobanianAVBakrisGLBlackHR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA.2003;289:2560–2572.
17.
GrundySMCleemanJIMerzCN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol.2004;44:720–732.
18.
Institute of Medicine. Energy. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.Washington, DC: National Academy Press; 2005:107–264.
19.
The National Heart Lung and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. 1998;51S–209S, Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.htm. Accessed January 5, 2008.
20.
Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, Md: US Department of Health and Human Services, Centers for Disease Control and Prevention, Public datasets 1999–2000, 2001–2002, 2003–2004, and 2005–2006, Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed May 26, 2008.
21.
National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation.2002;106:3143–3421.
22.
Agency for Healthcare Research and Quality. The medical expenditure panel survey, Rockville, Md: US Department of Health and Human Services, Full year consolidated data file 2000, 2002, and 2004. Available at: http://www.meps.ahrq.gov/mepsweb. Accessed May 26, 2008.
23.
GraudalNAGalloeAMGarredP. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA.1998;279:1383–1391.
24.
BrayGAVollmerWMSacksFM. A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium Trial. Am J Cardiol.2004;94:222–227.
25.
DallTZhangYChenYJ. Cost associated with overweight and obesity, high alcohol consumption, and tobacco use within the military health system's TRICARE Prime enrolled population. Am J Health Promot.2007;22:120–143.
26.
DattiloAMKris-EthertonPM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr.1992;56:320–328.
27.
MacMahonSCutlerJBrittainEHigginsM. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J.1987;8(suppl B):57–70.
28.
GoldsteinDJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord.1992;16:397–415.
29.
KleinSBurkeLEBrayGA. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation.2004;110:2952–2967.
30.
KnowlerWCBarrett-ConnorEFowlerSE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med.2002;346:393–403.
31.
WaddenTAAndersonDAFosterGD. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. Obes Res.1999;7:170–178.
32.
Pi-SunyerXBlackburnGBrancatiFL. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care.2007;30:1374–1383.
33.
NeterJEStamBEKokFJ. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension.2003;42:878–884.
34.
PoirierPGilesTDBrayGA. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol.2006;26:968–976.
35.
PoobalanASAucottLSSmithWC. Long-term weight loss effects on all cause mortality in overweight/obese populations. Obes Rev.2007;8:503–513.
36.
SimonsenMKHundrupYAObelEB. Intentional weight loss and mortality among initially healthy men and women. Nutr Rev.2008;66:375–386.
37.
DayJC. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050, US Bureau of the Census, Current Population Reports, P25–1130.Washington, DC: US Government Printing Office; 1996.
38.
SchoellerDARavussinESchutzY. Energy expenditure by doubly labeled water: validation in humans and proposed calculation. Am J Physiol.1986;250:R823–R830.
39.
LewingtonSClarkeRQizilbashN. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet.2002;360:1903–1913.
40.
LawMRWaldNJRudnickaAR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ.2003;326:1423.
41.
FinkelsteinEAFiebelkornICWangG. State-level estimates of annual medical expenditures attributable to obesity. Obes Res.2004;12:18–24.
42.
McMurrayJ. The health economics of the treatment of hyperlipidemia and hypertension. Am J Hypertens.1999;12:99S–104S.
43.
DallTZhangYFulgoniV. Predicted national productivity implications of calorie and sodium reductions in the American diet. Am J Health Promot.2009;23(6):423–430.
44.
MuntnerPDeSalvoKBWildmanRP. Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiol.2006;163: 913–920.
45.
WangTJVasanRS. Epidemiology of uncontrolled hypertension in the United States. Circulation.2005;112: 1651–1662.
46.
ElliottWJ. The economic impact of hypertension. J Clin Hypertens (Greenwich).2003;5(3suppl 2):3–13.
47.
FischerMAAvornJ. Economic implications of evidence-based prescribing for hypertension: can better care cost less?JAMA.2004;291:1850–1856.
48.
DegliELValpianiG. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics.2004;22:907–928.
49.
IsrailiZHHernandez-HernandezRValascoM. The future of antihypertensive treatment. Am J Ther.2007;14:121–134.
50.
HodgsonTACaiL. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care.2001;39:599–615.
